Skip to main content
BIO·ATLASby Bayes Pharma.ai
Search
AccountStart evaluation
AI drug discovery models/AI-Native Discovery Cos./Generate:Biomedicines
organization passport · Review date not recorded

Generate:Biomedicines

Generative biology turned into a clinical-stage pipeline.

1/7Evidence fields documented
60-SECOND EVALUATION VIEW

What should a scientist know before using Generate:Biomedicines?

UnresolvedEvidence direction is incomplete or not yet resolved
Best suited forPlatform · Discovery
Evidence supportsPrimary links may be present, but BioAtlas does not claim a review date without a record-level timestamp.
Evidence does not establishUniversal superiority, therapeutic success, clinical utility or regulatory acceptance.
Major limitationPerformance depends on the evaluation dataset and operating conditions.
CompareAdd to evaluationView evidence
Current registry recordVersion history pending0 recorded releases · Review date not recorded. A newer version is not assumed to be universally better.

What it is

Generate:Biomedicines treats protein creation as a generative problem via its Chroma model and internal platform, designing antibodies, peptides and other proteins across many targets. A Flagship Pioneering company, it has advanced generatively-designed candidates into the clinic and struck large pharma partnerships.

Evidence trail

BioAtlas keeps the path from source to decision visible. A connection records provenance; it does not imply that evidence is sufficient for every context.

Sources1 connectedPrimary resources and normalized claims
Claims0 normalizedNo normalized claim yet
EntityGenerate:Biomedicinesorganization · Version history pending
ReviewReview date not recordedReview date not claimed
ConclusionContext requiredAdd to an evaluation before operational use

Model passport

Entity typeorganization
OrganizationGenerate:Biomedicines
Organization founded2018
AccessLimited open access
Commercial useRestricted / verify terms
DeploymentHybrid
ComputeVendor managed
Domainscompany
Biology → representation → computation → evidence

How Generate:Biomedicines represents biology

organizationcompany

Category is navigation. These fields describe the model-specific computational transformation and deliberately override broad category defaults.

1 · Biological inputs
Disease hypothesis and multimodal evidence
2 · Input representation
Organization / platform dependent
3 · Internal representation
Multiple systems
4 · Architecture
Organization / discovery system
5 · Learning objective
Integrated discovery
6 · Output representation
Programs and evidence

Biological scale

Modalities & tasks

MultimodalPlatformDiscovery

Registry, claims and frontier intelligence

Versioned registry

Version history pending

0 version records · release year not yet normalized. Model-family identity remains separate from capability and access changes.

Explore version lineage →
Benchmark claim ledger

0 normalized claims

No task, dataset, split and metric claim has been normalized for this record yet.

Open claim intelligence →

Inputs and outputs

Inputs

Disease hypothesis and multimodal evidence

Outputs

Targets, candidates or development programs

Scientific and technical profile

Scientific principles

Generative protein designProgrammable biologyMulti-modality biologics

Technology

Chroma diffusion modelSequence + structure co-designWet-lab validation loops
Ideas before algorithms

Scientific lineage

Explore all foundations

These are transparent concept matches—not claims that one scientist alone caused this model. Each connection is based on the model’s recorded domain, scientific principles, technical terms or an explicit lineage link.

Medicinal chemistry & pharmacology

Selective toxicity and the ‘magic bullet’

Paul Ehrlich

Target selectivity, therapeutic index and mechanism-based screening remain central goals of drug discovery.

Matched concepts: target
Medicinal chemistry & pharmacology

Rational antimetabolite drug design

Gertrude B. Elion & George H. Hitchings

Mechanism-based design, pathway selectivity and iterative medicinal chemistry are direct descendants of this strategy.

Matched concepts: candidate
Biologics & genome engineering

Hybridoma production of monoclonal antibodies

Georges J. F. Köhler & César Milstein

Therapeutic antibodies, diagnostic antibodies and antibody discovery platforms became scalable and reproducible.

Matched concepts: biologic
Biologics & genome engineering

Directed evolution of enzymes and proteins

Frances H. Arnold

Generative protein design increasingly closes the loop with directed evolution and experimental selection to optimize function and manufacturability.

Matched concepts: protein design

Evaluation evidence

Dataset or evaluationNot yet curated
Task or metricNot yet extracted
Evidence statusNo task-specific benchmark record curated
Open source ↗

BioAtlas has not yet extracted a structured benchmark claim for this record.

Known limitations

  • Performance depends on the evaluation dataset and operating conditions.
  • A structured benchmark claim has not yet been extracted for this record.
  • Outputs require task-specific scientific and experimental validation.

Milestones

2018

Built on the Chroma generative model.

Evidence

Advanced generatively-designed proteins into trials.